OBJECTIVES: As suggested by in-vitro data, we hypothesize that subtypes of @entity984 mutated @entity1149 ( @entity1149 ) respond differently to chemotherapy regimens. METHODS: @entity1 with advanced @entity1149 and known @entity984 mutation, treated with first-line @entity902 -based chemotherapy, were retrieved from hospital databases. PRIMARY OBJECTIVE: to investigate overall response rate (ORR), progression free survival (PFS) and @entity1349 ( @entity1349 ) between different types of @entity902 -based chemotherapy per type of @entity984 mutation. RESULTS: 464 @entity1 from 17 hospitals, treated between 2000 and 2013, were included. The majority of @entity1 had stage IV disease (93%), had a history of smoking (98%) and known with an @entity420 (91%). Most common types of @entity984 mutation were @entity34831 (46%), @entity22563 (20%) and @entity4706 (10%). @entity902 was combined with pemetrexed (n=334), @entity6023 (n=68) or @entity136 (n=62). @entity1 treated with @entity6023 had a significant improved ORR (50%) compared to pemetrexed (21%) or @entity136 (25%; p<0.01). @entity1 treated with bevacizumab in addition to @entity6023 (n=38) had the highest ORR (62%). The PFS was significantly improved in @entity1 treated with @entity6023 compared to pemetrexed (HR=0.72, p=0.02), but not @entity1349 (HR=0.87, p=0.41). In @entity1 with @entity22563 , significantly improved ORR (p<0.01) was observed for @entity6023 , but not PFS or @entity1349 . @entity1 with @entity34831 or @entity4706 mutation had comparable ORR, PFS and @entity1349 in all treatment groups. CONCLUSION: @entity984 mutated @entity1149 @entity1 treated with @entity3907 -based chemotherapy had best ORR. Response to chemotherapy regimens was different in types of @entity984 mutation. Especially @entity1 with @entity22563 had better response to @entity3907 treatment.

Comparison of clinical outcome after first-line @entity902 -based chemotherapy in different types of XXXX mutated advanced @entity1149 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity22563 :: ('p|SUB|G|12|V', 'ProteinMutation') :: ['G12V'] @entity6023 :: ('MESH:D043823', 'Chemical') :: ['taxanes'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity4706 :: ('p|SUB|G|12|D', 'ProteinMutation') :: ['G12D'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['Platinum', 'platinum'] @entity34831 :: ('c|SUB|G|12|C', 'DNAMutation') :: ['G12C'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity984 :: (3845,Gene) :: ['KRAS']
